PharmaEngine (4162) — Capital Reinvestment Ratio
Latest as of September 2025:
0.00x
PharmaEngine (4162) has a Capital Reinvestment Ratio of 0.00x as of September 2025, meaning it reinvests 0% of its operating cash flow (NT$53.01 Million) in capital expenditures (NT$115.00K). See PharmaEngine free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.00x
Capex / Operating Cash Flow
Operating Cash Flow
NT$53.01 Million
TWD
Capital Expenditures
NT$115.00K
TWD
Data as of
Sep 2025
Most recent filing
PharmaEngine Capital Reinvestment Ratio (2011–2024)
This chart tracks PharmaEngine's Capital Reinvestment Ratio across 12 annual periods.
Annual Capital Reinvestment Ratio for PharmaEngine (2011–2024)
Year-by-year Capital Reinvestment Ratio for PharmaEngine from 2011 to 2024. For live market cap and broader valuation context, see PharmaEngine (4162) total market value.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 0.00x | NT$456.73 Million | NT$1.42 Million | ▼ -16.9% |
| 2023 | 0.00x | NT$256.97 Million | NT$958.00K | ▼ -80.9% |
| 2022 | 0.02x | NT$202.01 Million | NT$3.94 Million | ▲ +7825.9% |
| 2021 | 0.00x | NT$929.67 Million | NT$229.00K | ▼ -97.4% |
| 2020 | 0.01x | NT$64.77 Million | NT$608.00K | ▼ -27.4% |
| 2019 | 0.01x | NT$16.08 Million | NT$208.00K | ▲ +1790.4% |
| 2018 | 0.00x | NT$745.23 Million | NT$510.00K | ▼ -48.0% |
| 2016 | 0.00x | NT$870.38 Million | NT$1.15 Million | ▼ -95.0% |
| 2015 | 0.03x | NT$447.99 Million | NT$11.80 Million | ▲ +3535.1% |
| 2014 | 0.00x | NT$131.09 Million | NT$95.00K | ▼ -40.1% |
| 2012 | 0.00x | NT$68.64 Million | NT$83.00K | ▼ -58.7% |
| 2011 | 0.00x | NT$275.49 Million | NT$806.00K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow